Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Intestinal Neoplasms 3Gastrointestinal Neoplasms 3Gastrointestinal Diseases 3Colorectal Neoplasms 3Rectal Neoplasms 2Digestive System Neoplasms 2Rectal Diseases 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Intestinal Diseases 1Digestive System Diseases 1Colonic Neoplasms 1

Interventions

selpercatinib 2pembrolizumab 2abemaciclib 2Pemetrexed 2Nivolumab 2Irinotecan 2Fulvestrant 2Abiraterone Acetate 2ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pamiparib 1palbociclib 1osimertinib 1onapristone 1olaparib 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1elacestrant 1cobimetinib 1abiraterone 1Trastuzumab 1Taxes 1Tamoxifen 1STX-478 1Radiation 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Site × 5,10-methylenetetrahydrofolic acid × Clear all
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡